drugset / Trial / NCT03315052

Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects

NCT03315052

Phase 4 Withdrawn Montefiore Medical Center
RandomizedSingle-groupOpen-labelTreatment

Summary

Our hypothesis is that budesonide will provide effective hepatic ISP that will replace prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and calcineurin-associated complications often observed in the OLT population. This study is intended to investigate the therapeutic potential of this ISP combination.

Timeline

Start
2019-01
Primary completion
2021-01
Completion
2022-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 9 mg Oral
Comparator Prednisone Other / unclassified
Background Mycophenolate Mofetil Small molecule
Background Tacrolimus Small molecule